KCNE1L Inhibitors

Chemical inhibitors of KCNE1L can exert their effects through various mechanisms that pertain to the regulation of potassium ion flow within cardiac cells. Amiodarone, for example, by interacting with potassium channels that share functional similarities with KCNE1L, can alter the repolarization phase of the cardiac action potential where KCNE1L is active. Clofilium Tosylate and E-4031 have a more targeted action on potassium channels, which are modulated by KCNE1L, thus indirectly affecting the protein's function by inhibiting the delayed rectifier potassium current. Sotalol, while being a beta-blocker, also has the capacity to block IKr potassium channels. Since KCNE1L is associated with the modulation of IKr currents, Sotalol can reduce the repolarization current that KCNE1L is known to regulate, resulting in an indirect inhibition of its function.

Similarly, Dofetilide and Ibutilide are agents that block IKr potassium channels, which indirectly impedes the functioning of KCNE1L due to its role in those channels' modulation. Azimilide's dual action on both IKs and IKr channels results in a comprehensive inhibition effect on the currents that KCNE1L helps to modulate. Chromanol 293B, although it primarily inhibits IKs channels, indirectly affects KCNE1L's modulation of these channels. Tedisamil extends its blocking action to various potassium currents including those regulated by KCNE1L, thus indirectly inhibiting the protein. Linopirdine, a blocker of Kv7/KCNQ channels, alters potassium channel activity which can extend to KCNE1L, affecting its role in cardiac cells. Disopyramide and Almokalant both target potassium channels as well, with their actions leading to an inhibition of the repolarization currents that KCNE1L modulates, indirectly suppressing the protein's functional role in the cardiac action potentials.